Late-breaking phase 2 immunoPRISM trial data show teclistamab superior to Len/Dex in high-risk smoldering myeloma, with higher CR rates and PFS.
Omar Nadeem, MD
Advertisement
Omar Nadeem, MD, is clinical director of the Myeloma Immune Effector Cell Therapies Program at Dana-Farber Cancer Institute.
Articles by Omar Nadeem, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV
2
Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure
3
Real-World Data Show MASH Progresses Faster Than Trials Suggest
4
Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO
5